Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
Émilie Le Rhun, Matthias Gückenberger, Marion Smits, et al.
Annals of Oncology (2021) Vol. 32, Iss. 11, pp. 1332-1347
Open Access | Times Cited: 371

Showing 1-25 of 371 citing articles:

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari, Fabrice André, Carlos H. Barrios, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1475-1495
Open Access | Times Cited: 844
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lizza E.L. Hendriks, Keith M. Kerr, Jessica Menis, et al.
Annals of Oncology (2023) Vol. 34, Iss. 4, pp. 339-357
Open Access | Times Cited: 418
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lizza E.L. Hendriks, Keith M. Kerr, Jessica Menis, et al.
Annals of Oncology (2023) Vol. 34, Iss. 4, pp. 358-376
Open Access | Times Cited: 319
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
Rupert Bartsch, Anna S. Berghoff, Julia Furtner, et al.
Nature Medicine (2022) Vol. 28, Iss. 9, pp. 1840-1847
Open Access | Times Cited: 286
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
George D. Demetri, Filippo de Braud, Alexander Drilon, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 7, pp. 1302-1312
Open Access | Times Cited: 141
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
Ayal A. Aizer, Nayan Lamba, Manmeet S. Ahluwalia, et al.
Neuro-Oncology (2022) Vol. 24, Iss. 10, pp. 1613-1646
Open Access | Times Cited: 95
Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 90
Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer
Julien Mazières, Paul K. Paik, Marina Chiara Garassino, et al.
JAMA Oncology (2023) Vol. 9, Iss. 9, pp. 1260-1260
Open Access | Times Cited: 56
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer
Pasi A. Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 7, pp. 808-820
Open Access | Times Cited: 54
Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Émilie Le Rhun, Michael Weller, Martin J. van den Bent, et al.
ESMO Open (2023) Vol. 8, Iss. 5, pp. 101624-101624
Open Access | Times Cited: 51
Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline
Puneeth Iyengar, Sean All, Mark F. Berry, et al.
Practical Radiation Oncology (2023) Vol. 13, Iss. 5, pp. 393-412
Closed Access | Times Cited: 50
Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases
Rupert Bartsch, Anna S. Berghoff, Julia Furtner, et al.
Neuro-Oncology (2024) Vol. 26, Iss. 12, pp. 2305-2315
Open Access | Times Cited: 23
Multi‐omics technologies and molecular biomarkers in brain tumor‐related epilepsy
Yaoqiang Du, Rusong Li, Danqing Fu, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 4
Open Access | Times Cited: 18
Targeting brain metastases in breast cancer
Chiara Corti, Gabriele Antonarelli, Carmen Criscitiello, et al.
Cancer Treatment Reviews (2021) Vol. 103, pp. 102324-102324
Closed Access | Times Cited: 79
How we treat patients with metastatic HER2-positive breast cancer
Guilherme Nader Marta, Diogo Martins-Branco, Evandro de Azambuja
ESMO Open (2022) Vol. 7, Iss. 1, pp. 100343-100343
Open Access | Times Cited: 56
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Cátia Monteiro, Lauritz Miarka, María Perea-García, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 752-765
Open Access | Times Cited: 56
Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment
Yingze Zhu, Yishuang Cui, Xuan Zheng, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2022) Vol. 1868, Iss. 12, pp. 166557-166557
Open Access | Times Cited: 48
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
Yuanbin Chen, Luis Paz‐Ares, Niels Reinmuth, et al.
JTO Clinical and Research Reports (2022) Vol. 3, Iss. 6, pp. 100330-100330
Open Access | Times Cited: 38
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Martin Reck, Tudor‐Eliade Ciuleanu, Jong-Seok Lee, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 8, pp. 1055-1069
Open Access | Times Cited: 38
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
Naoki Niikura, Takashi Yamanaka, Hironori Nomura, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 38
Amino Acid PET in Neurooncology
Norbert Galldiks, Philipp Lohmann, Gereon R. Fink, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 5, pp. 693-700
Open Access | Times Cited: 34
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe
Tiuri E. Kroese, Hanneke W.M. van Laarhoven, Sebastian F. Schoppman, et al.
European Journal of Cancer (2023) Vol. 185, pp. 28-39
Open Access | Times Cited: 31
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
Laura Alder, Dario Trapani, Claire Bradbury, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 30
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
Seock‐Ah Im, Alessandra Gennari, Y.H. Park, et al.
ESMO Open (2023) Vol. 8, Iss. 3, pp. 101541-101541
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top